![](http://bsg-s.nbxc.com/site_themes/common/inquiry_popup/images/close.png)
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Gileadの新しい薬物vemlidy(Tenofovir Alafenamide Fumarate、25 mg、1日1回)は、補償肝疾患における慢性B型肝炎ウイルス感染のための米国FDAによって承認されました。 Vemlidyは革新的な標的Tenofovir Prodrugです。前の製品Viread(Tenofovir Disoproxil Fumarate、Tenofidisisoproxilfumarate)300mgと比較して、それは投与量の10分の1未満だけ必要です。同様の抗ウイルス効果を得る。
製品グループ : API中間体 > テノホビルアラフェナミドフマル酸塩中間体
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.